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cancer in patients with increased copy
number of the topoisomerase I gene
Iben Kümler1* , Eva Balslev2, Jan Stenvang3, Nils Brünner3, Bent Ejlertsen4, Erik Hugger Jakobsen5 and
Dorte Lisbet Nielsen1
Abstract
Background: Treatment options in metastatic breast cancer are limited. New therapies preferable with predictive
biomarkers are needed. The aim of these trials was to investigate if gene copy number of the topoisomerase 1
gene was predictive of response to the topoisomerase inhibitor irinotecan.
Methods: Two open-label, single-arm phase II studies including HER2 positive and negative patients were
conducted. Patients were eligible for inclusion if the primary tumor or a metastatic lesion had increased expression
of the topoisomerase 1 gene defined as a TOP1 gene copy number of ≥4 or a TOP1/CEN20 ratio of ≥2. Patients
were treated with irinotecan +/− trastuzumab weekly for 4 weeks following 2 weeks break, until progression or
unacceptable toxicities. Evaluation scans were performed every 6 weeks. Primary endpoint was clinical benefit rate
defined as the fraction of patients with stable disease for ≥4 months.
Results: The pre-planned number of 18 patients in each trial was not reached, thus no formal statistical analysis
could be performed. Nine patients with HER2 negative disease and three patients with HER2 positive disease were
included. Three patients obtained a partial remission and two patients had SD.
Conclusions: The trials did not include the planned number of patients. No association between gene copy
number of the topoisomerase 1 gene and response to irinotecan could be proved, however a clinical benefit was
found in 5/12 patients and in 2/3 patients with HER2 positive disease. This could call for further investigation of the
drug in the metastatic setting, especially in HER2 positive BC.
Trial registration: Eudract registration numbers 2012–002348-26 and 2012–002347-23. Registration date August
20th 2012.
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Introduction
Despite improvements in the adjuvant treatment of
breast cancer (BC), still about 20% of patients with pri-
mary BC will experience loco-regional or distant recur-
rence [1]. Chemotherapy is the only established option
for patients with oestrogen receptor (ER) negative and
human epidermal receptor 2 (HER2) negative disease. In
HER2 positive disease, the blocking of HER2 signalling
is essential and is to a great extent combined with
chemotherapy. In patients with ER positive, advanced
disease chemotherapy is also recommended in case of
rapid progression or suspicion of endocrine resistance.
Sequential monotherapy with a cytotoxic drug is recom-
mended by international guidelines in any case of advanced
disease. Anthracyclines or taxanes are recommended as
first-line chemotherapy for those patients who have not re-
ceived the drugs in the adjuvant setting. In the western
world, a large number of women have been exposed to
both drugs at the time of recurrence, excluding their use in
the metastatic setting. Other treatment options consist of a
number of standard drugs used in random order, with vary-
ing response rates, often declining with increasing numbers
of treatment lines [2–5]. None of the chemotherapeutics
used today are known to be associated with any biomarkers
predictive of response.
Irinotecan is a topoisomerase I (TOP1) inhibitor
widely used in the treatment of colorectal cancers but
only investigated for the use in metastatic BC in a very
limited number of studies [6]. Clinical trials have shown
modest response rates in metastatic BC, ranging from 5
to 23% in unselected populations, often including pa-
tients with several prior treatment regimens for meta-
static disease [6].
Tumor levels of TOP1 have been proposed as a poten-
tial biomarker for response to irinotecan. Both gene
copy number (CN), TOP1/centromere 20 (CEN-20) ra-
tio, protein expression and mRNA expression have been
used to identify expression levels of TOP1 in colorectal
cancer but with conflicting outcome [7–11].
Previously, we have shown that approximately 30% of
patients with breast cancer are amplified for the TOP1
gene [12].
Thus, we decided to investigate the efficacy of irinote-
can for treatment of patients with metastatic BC and in-
creased CN of the TOP1 gene.
Materials and methods
Study design and objectives
Two identical trials including HER2 positive respectively
HER2 negative patients were conducted. Both trials were
open label, single-arm, non-randomized, multi-center,
phase II studies. Based on Simon’s two-stage Minimax
design, using a level of significance of 0.05 (α = 0.05) and
a power of 80% (β = 0.20), 19 patients were planned to
be included in each of the trials in order to find a clinical
benefit rate (CBR) of at least 30%. If less than 7/19 pa-
tients obtained clinical benefit (CB), further inclusion
would be ceased. If 7 or more patients obtained clinical
benefit, another 20 patients would be included.Primary
endpoint was CBR defined as the fraction of patients
obtaining stable disease for ≥4 months, complete or par-
tial response according to RECIST criteria version 1.1.
Secondary endpoints included time to progression, time
to death and toxicity.
Both trials were multi center, including 7 Danish de-
partments of Oncology and endorsed and organized in
collaboration with the Danish Breast Cancer Cooperative
Group.
Patients
Eligibility criteria included progressive disease, a max-
imum of 4 previous chemotherapy regimens for meta-
static disease, measurable disease by RECIST 1.1 [13],
and increased CN of the TOP1 gene.
Any previous endocrine therapy was allowed.
Both studies were approved by the local Ethics Com-
mittee and the Danish Medicines Agency (H-1-2012-066
and H-1-2012-065, Eudract 2012–002348-26 and 2012–
002347-23).
TOP1 analysis
TOP1 gene CN was determined using FISH (fluores-
cence in situ hybridization) as previously described [12].
Patients were considered eligible if TOP1 gene copy
number CN in either the primary tumour or metastatic
lesion was ≥4 and/or the TOP1/CEN20 ratio was ≥2.
Treatment
Patients with HER2 negative disease were initially treated
with intravenous irinotecan 100mg/m2 weekly for 4 weeks
followed by two weeks break. The dose was subsequently
reduced to 75mg/m2 weekly due to toxicities. Based on a
review of previous clinical trials with irinotecan in meta-
static BC the initial dose of 100mg/m2 was chosen as this
regime had produced the best response rates [6, 14].
For patients with HER2 positive disease the same treat-
ment was administered adding trastuzumab 6mg/kg every
third week. Treatment was continued until disease pro-
gression or unacceptable toxicity.
Evaluation
CT scans were performed before treatment initiation
and then every 6 weeks and assessed according to
RECIST version 1.1.
Results
From October 2012 to July 2016, 740 biopsies were col-
lected for TOP1 analyses. 46 samples were not suitable
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for analysis due to either poor quality of the FISH sig-
nals or lack of tumor tissue in the sample. Thus 694 bi-
opsies were eligible for analysis. 477 samples (69%) were
primary mamma carcinomas, the remaining were ob-
tained from various metastatic lesions. The TOP1/CEN
ratio was ≥2 in 7% of the samples. The ratio varied from
0,35 to 8,18 with a median ratio of 1,33 (Table 1).
A TOP1 gene CN of ≥4 was found in 15.6% of the
samples ranging from 1,01 to 15 and with a median of 2,
63 CN. An increase in both TOP1/CEN ratio and TOP1
gene CN was found in 5% of the samples. Totally 18% of
the samples exhibited an increased TOP1 expression ei-
ther in the TOP1/CEN 20 ratio, the gene CN or both.
Nine patients were included in the HER2 negative
protocol while three patients were included in the HER2
positive protocol.
The reason for including only 12 patients in total was
mainly clinician’s reluctance to try an investigational
drug prior to standard therapies. As up to 4 lines of pre-
vious chemotherapies were allowed, several eligible pa-
tients were never offered treatment in the protocol as
their performance status had deteriorated once standard
treatments were completed.
Due to poor recruitment the protocols were termi-
nated without fulfilling the planned inclusion number of
19 patients in each of the two protocols. The small num-
ber of patients precludes any formal statistical analyses
and thus data are only descriptive.
Patient characteristics are given in Table 2. All patients
had received at least 2 prior chemo regimens for meta-
static disease and 10 patients had received 3 or 4 prior
regimens. One patient had primary disseminated disease.
All patients were performance status 0–1.
In the HER2 negative cohort, one patient obtained a
partial remission lasting 10months; two patients had
stable disease lasting 8 months and 7months, respect-
ively. All patients had bone metastases, two had liver
metastases and the last patient had lymph node, lung
and pleura metastases. The patient with PR had received
3 chemotherapy regimens prior to inclusion. The pa-
tients with SD had received 3 and 2 chemotherapy regi-
mens respectively, prior to inclusion.
One patient withdrew after first treatment due to severe
comorbidities and three patients withdrew before evaluation
was performed due to toxicity (diarrhea). Three patients had
progressive disease before 4months of treatment.
Three patients were enrolled in the HER2 positive study.
One patient had partial remission lasting for 10months
and one patient withdrew due to clinical progression prior
to evaluation. The third patient withdrew informed consent
after 2 treatment cycles, the following CT scan showed par-
tial remission. The patient with stable disease had metasta-
ses to lymph nodes and pleura and had received 4 chemo
regimens prior to inclusion in the study while the patient
who withdrew consent had bone, lung and pleural metasta-
ses and had received 3 prior chemotherapy regimens.
Among the 3 patients with PR and SD in the HER2
negative trial two had a mean CN of > 6 while all non-
responders had CN below. Looking at the TOP1/CEN-
20 ratio 2/3 responders had ratios > 2 while only one of
the non-responders also exhibited a ratio above 2. The
single person with confirmed response in the HER2
positive trial had a TOP1/CEN2 ratio of 2.87 and a mean
CN of 5 while the patient with PR who withdrew con-
tent had a CN of 7 and a TOP1/CEN2 of 3.3.
Toxicities
Initially patients were treated with irinotecan 100mg/m2.
However as two out of four patients experienced nausea
Table 1 TOP1 analyses
No of Analyses 694
No of patients 580
No of patients with more than 1 biopsy 109
TOP1/CEN20 (median) 0,35–8,18 (1,33)
Gene copy number (median) 1,01–15 (2,63)
Table 2 Patients characteristics
Number of patients 12
Age Median
50–74 64
PS
0 4 (33%)
1 8 (67%)
Receptor status
ER+ 12 (100%)
HER2+ 3 (25%)
Adjuvant therapy
chemotherapy 7 (58%)
endocrine 7 (58%)
Primary disseminated disease 1 (8%)
Prior chemo regimens for metastatic disease
2 2 (17%)
3 6 (50%)
4 4 (33%)
Metastatic sites
Lymph nodes 5 (42%)
Bone 10 (83%)
Lung 6 (50%)
Pleura 5 (42%)
Liver 8 (67%)
Skin 1 (8%)
Ipsilateral breast 2 (17%)
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and diarrhea and were withdrawn from the study, the dose
was reduced to 75mg/m2 and hereafter no dose limiting
toxicities were observed. Generally the treatment was well
tolerated hereafter.
No suspected unexpected serious adverse advents
occurred.
Discussion
The aim of the two studies was to investigate if in-
creased CN of the TOP1 gene could be used as a pre-
dictive biomarker for response to irinotecan. As the
planned number of patients was not fulfilled no formal
statistical analyses could be done.
Several explanations for the slow recruitment may be
found. Prior to initiating the clinical studies we had in-
vestigated the frequency of TOP1 CN gain in normal
breast tissue and in samples from primary BC. Based on
these results we had anticipated that up to 30% of pa-
tients with BC would have increased CN of the TOP1
gene [15]. In the clinical trials only 19% of patients ful-
filled the criteria for increased CN. Furthermore, reluc-
tance to try a new drug before having tried standard
drugs lead to a protocol amendment allowing up to 4
prior lines of chemotherapy. This resulted in a substan-
tial number of patients with poor performance status
once inclusion into the trials was relevant.
Moreover, specific for the HER2 positive protocol,
trastuzumab emtansine (TDM-1) was approved in No-
vember 2013 and has proven to be a very effective drug
leading to long progression free periods in a large part
of patients with HER2 positive disease and thereby post-
poning the need for experimental treatments.
The chosen cut-off value for TOP1 CN could be de-
bated. As no clinical data pertaining to TOP1 in BC have
been identified we had to base the cutoff values purely
on theoretical assumptions. Dual FISH probes rely on
the ratio between the number of signals from the target
gene and the number of signals from a reference region
on the same chromosome. Thus, a TOP1/CEN-20 ratio
≠ 1 would imply an imbalance due to excess copies or
loss of either the TOP1 gene or chromosome 20. How-
ever, whether the cutoff should be set at 1.5, 2.0 or even
higher is speculative in the absence of clinical data to
support such a decision. For the mean CN we chose ≥4
as the threshold for “gain”. This is not totally in line with
recommendations for HER2 as these states that in case
of a HER2/CEN-17 ratio below 2.0 the CN must be ≥6
[16]. As no clinical data could guide us we decided to
use ≥4 as this would reflect an excess of the gene even
in the case of counting signals in a cell in the S phase.
The very limited data from our clinical trials, makes it
impossible to investigate if changes in the cutoff value
for CN will have any clinical implications although 3/5
responders did have a mean CN of > 6 whereas all non-
responders had CN below.
Few studies have reported the use of irinotecan in
metastatic BC. The most recent study by Perez et al. in-
cluded 852 patients randomly assigned to either etrino-
tecan or treatment of physician’s choice [17].
Patients were heavily pretreated with up to five previous
regimens for metastatic disease. The trial did not demon-
strate improved overall survival in the etirinotecan group;
however the toxicity profile was more favorable for etirino-
tecan compared to physician’s choice. In this trial several
biomarkers were analyzed, among these topoisomerase 1
and 2. So far no results on these biomarkers have been
published. To our knowledge, no other studies have investi-
gated the topoisomerases in relation to irinotecan in BC al-
though this might be a biomarker for response if properly
investigated and validated.
Furthermore topoisomerase 1 inhibitors like irinotecan
might actually be superior to other types of chemother-
apy in recurrent BC since a previous study in irinotecan
resistant breast cancer cell lines found no cross resist-
ance between taxanes and irinotecan [18] .
However, as our study did not fulfill the planned in-
clusion no firm conclusions on the presented data
can be drawn.
Conclusion
In conclusion our trials did not succeed in proving an
association between gene CN of the TOP1 gene and re-
sponse to irinotecan. Since the studies were initiated
novel treatment opportunities have emerged in the
metastatic setting but even so the need for predictive
biomarkers is still desperately wanted. Even though
among heavily pretreated patients, 5 out of 12 patients
totally and 2 out of 3 patients with HER2 positive dis-
ease did have a clinical benefit of treatment with irinote-
can, our study did not fulfill the planned inclusion and
therefore no firm conclusions can be drawn. Future ran-
domized trials are warranted to identify the best chemo-
therapeutic options for metastatic breast cancer patients
with increased TOP1 gene copy numbers.
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